Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M.
Reinhart K, et al. Among authors: kaul m.
Crit Care Med. 2001 Apr;29(4):765-9. doi: 10.1097/00003246-200104000-00015.
Crit Care Med. 2001.
PMID: 11373466
Clinical Trial.